<DOC>
	<DOCNO>NCT02135705</DOCNO>
	<brief_summary>This global product exposure registry multicentre , long-term , prospective , observational cohort study ( exposure registry ) , design evaluate long term safety effectiveness lomitapide .</brief_summary>
	<brief_title>LOWER : Lomitapide Observational Worldwide Evaluation Registry</brief_title>
	<detailed_description>To evaluate occurrence adverse event special interest , long term effectiveness lomitapide , evaluate whether prescribers lomitapide follow screen monitor recommendation specify product labeling .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Adult patient ( age â‰¥18 year ) meet one follow two criterion : Initiating treatment lomitapide time registry enrolment , initiate treatment lomitapide within 15 month prior enrolment registry lomitapide commercial availability country . Patients ability understand requirement study provide write informed consent comply study data collection procedure . Patients receive lomitapide clinical trial Patients receive investigational agent , define drug biologic agent lomitapide receive MA country participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>